Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme hopes to purchase rest of IG Laboratories:

This article was originally published in Clinica

Executive Summary

Genzyme wishes to purchase the remaining shares of IG Laboratories, the genetic testing company in which it already has a 69% stake. It has approached IG's directors and proposed a tax-free merger under which IG stockholders would receive 0.12368 Genzyme shares for each IG share. This values IG shares at $4.76 - a premium of 29% on the share price prior to the offer - and the total transaction at $14 million.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts